Previous 10 | Next 10 |
Polen Capital is a high-conviction growth investment manager. We scour the globe in search of the highest quality, sustainable companies to invest in. Over the first quarter of 2022, the Polen International Growth Composite Portfolio returned -13.94% gross and -14.17% net of fees, res...
No Rating Change. Medpace remains an attractive business selling at a discount to its intrinsic value. Management is aggressively repurchasing shares, a signal of confidence and a boost to EPS. For further details see: Medpace Holdings: Update Following Q1 FY2022 Earning...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 5:20pm PT. Any changes to ...
IQVIA has the potential to outperform the market in a higher inflation environment. Significant growth potential with projected 17.72% FCF and 11.68% EBIT CAGR over the next 5 years. Decentralized clinical trials, the emergence of virtual trials, blockchain technologies, AI and ML...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2022 Q1 earnings call. For further details see: ICON Public Limited Company 2022 Q1 - Results - Earnings Call Presentation
BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...
ICON Public Limited Company (ICLR) Q1 2022 Earnings Conference Call April 28, 2022, 8:00 AM ET Company Participants Steve Cutler – Chief Executive Officer Brendan Brennan – Chief Financial Officer Kate Haven – Vice President Investor Relations Conference Call Participants...
Icon press release (NASDAQ:ICLR): Q1 Non-GAAP EPS of $2.76 beats by $0.07. Revenue of $1.9B (+121.4% Y/Y) beats by $10M. Record net business wins in the quarter of $2,426 million; a net book to bill of 1.28. Closing backlog of $19.6 billion, an increase of 2.7% on Q4 2021 or an increase of 9....
Highlights Record net business wins in the quarter of $2,426 million; a net book to bill of 1.28. Closing backlog of $19.6 billion, an increase of 2.7% on Q4 2021 or an increase of 9.8% year over year on a Combined Company basis. Quarter 1 revenue of $1,902 mil...
Icon (NASDAQ:ICLR) is scheduled to announce Q1 earnings results on Thursday, April 28th, before market open. The consensus EPS Estimate is $2.69 (+30.6% Y/Y) and the consensus Revenue Estimate is $1.89B (+120.2% Y/Y). Over the last 2 years, ICLR has beaten EPS estimates 63% of the time and ha...
News, Short Squeeze, Breakout and More Instantly...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...
2024-05-31 07:00:07 ET David Windley from Jefferies issued a price target of $390.00 for ICLR on 2024-05-31 05:48:00. The adjusted price target was set to $390.00. At the time of the announcement, ICLR was trading at $322.92. The overall price target consensus is at $265...